SOLIGENIX, INC. (SNGX): Nasdaq/NYSE listing notice — Soligenix terminates HyBryte program after Phase 3 futility; receives Nasdaq bid price deficiency notice

SOLIGENIX, INC.

Received Nasdaq notice for non-compliance with $1.00 minimum bid price; 180 days until Dec 7, 2026 to regain compliance.
Board terminated HyBryte (synthetic hypericin) development program after DMC recommended halt for futility.
Expected wind-down charges of approximately $70,000 from closing FLASH2 trial.
Consulting CMO Richard Straube stepped down; duties transitioned to Medical Director Christopher Pullion.
Company will evaluate strategic alternatives including M&A and advancing dusquetide (SGX945) for Behçet's Disease.

item 3.01 item 5.02 item 8.01 item 9.01

Featured in Daily 8-K Digest

Selected #10 for 2026-06-12. Read digest

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard C. Straube

Consulting Chief Medical Officer

SNGX · SOLIGENIX, INC.

Effective: 2026-06-11
Filed: June 12, 2026, 4:05 PM ET

Dr. Straube ceased serving as the Company's Consulting Chief Medical Officer.

Role change

Christopher Pullion

Medical Director

SNGX · SOLIGENIX, INC.

Filed: June 12, 2026, 4:05 PM ET

Dr. Straube's responsibilities will be transitioned to Dr. Christopher Pullion, the Company's Medical Director.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

June 10, 2026, Soligenix, Inc. (the “Company”) received a written notice (the “Bid Price Notice”) from the Listing Qualifications department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market under the symbol “SNGX,” and the Company is currently monitoring th

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard C. Straube departed as Consulting Chief Medical Officer at SOLIGENIX, INC..

Action: ceased serving
Role: Consulting Chief Medical Officer

Exact text from the filing

Dr. Straube ceased serving as the Company's Consulting Chief Medical Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

Christopher Pullion changed role as Medical Director at SOLIGENIX, INC..

Action: transitioned responsibilities
Role: Medical Director

Exact text from the filing

Dr. Straube's responsibilities will be transitioned to Dr. Christopher Pullion, the Company's Medical Director.

View on SEC.gov

95 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

SOLIGENIX, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-073430

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.